

Erratum: Assessment of some synthesized novel 9-substituted tetrahydroacridine derivatives in diabetic disease management in rats

In the article titled “Assessment of some synthesized novel 9-substituted tetrahydroacridine derivatives in diabetic disease management in rats” published in pages 53–61, issue 1, vol. 16 of Egyptian Pharmaceutical Journal^[1], the sentences “Analysis: for C₁₈H₁₉N₃O (283.2); calculated: C: 76.27, H: 6.70, N: 14.83%; found: C: 75.75, H: 6.55, N: 15.32%.” and “Analysis: for C₁₈H₁₉N₃O₂(309.2) Calcd, C, 70.00; H, 6.14, N, 13.59%, Found, C, 70.15, H, 6.55; N, 13.32%.” under the “Materials and Methods” section are written incorrectly. The correct sentences should read as “Analysis: for C₁₈H₂₀N₃ (276.2); calculated: C: 78.26, H: 7.24, N: 15.21%; found: C: 77.66, H: 6.90, N: 14.70%.” and “Analysis for C₁₈H₂₀N₃ (276.2) Calcd, C, 78.26, H: 7.24, N: 15.21%; found: C: 77.66, H: 6.90, N: 14.70%.” respectively.

Reference

1 Abdel Megeed RM, Ghanem HZ, Kamel MM, Bakeet MF, Abdel-Hamid AHZ. Assessment of some synthesized novel 9-substituted tetrahydroacridine derivatives in diabetic disease management in rats. Egypt Pharmaceut J 2017;16:53–61.

DOI: 10.4103/epj.epj_27_17